CompletedNot Applicable

Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.

France30 participantsStarted 2021-12-28

Plain-language summary

Systemic sclerosis is an autoimmune disease in which the hand is responsible for 75% of the overall disability. Management is based on systemic treatments combined with kinesitherapy aimed at maintaining joint amplitudes, improving muscle strength and preventing stiffness. The aim of this study is to describe and compare the average spontaneous and attempted reduction range of motion limitations between the dominant and contralateral hand.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Group 1 : * Major patient * Diagnosis of diffuse or limited cutaneous systemic sclerosis according to the new ACR/EULAR criteria * Cochin hand score less than or equal to 16 * Group 2 : * Major patient * Diagnosis of diffuse or limited cutaneous systemic sclerosis according to the new ACR/EULAR criteria * Cochin hand score greater than 16. Exclusion Criteria: * Overlap syndrome (Sharp or scleromyositis 2) * Patient with another autoimmune disease * History of surgery or trauma to the hand with proven functional sequelae * Presence of synovitis * Patient with Dupuytren's disease

What they're measuring

Measurement of joint amplitudes

Timeframe: at inclusion

Trial details

NCT IDNCT05171114

SponsorUniversity Hospital, Limoges

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-22

View on ClinicalTrials.gov More Scleroderma, Systemic trials